# Diabetic Kidney Disease

## Introduction

Diabetic kidney disease is the leading cause of end-stage renal disease worldwide, accounting for approximately 40 to 50 percent of incident ESRD. It affects 30 to 40 percent of patients with both type 1 and type 2 diabetes and is associated with a markedly increased cardiovascular mortality risk that is 10 to 20 times higher than in the general population. The traditional model of DKD progression follows a sequence from glomerular hyperfiltration to microalbuminuria to macroalbuminuria and eventually declining GFR leading to ESRD. However, the entity of non-albuminuric DKD is increasingly recognized, affecting 30 to 40 percent of type 2 diabetes patients with reduced GFR who have no albuminuria, challenging the classical paradigm and underscoring the heterogeneity of diabetic renal disease.

## Pathophysiology

### Hemodynamic Factors

The hemodynamic injury in DKD is driven by glomerular hyperfiltration, characterized by an increased single-nephron GFR resulting from afferent arteriolar vasodilation mediated by nitric oxide and prostaglandins combined with efferent arteriolar vasoconstriction driven by angiotensin II. This hemodynamic imbalance produces elevated intraglomerular pressure, or glomerular hypertension, which subjects podocytes to chronic mechanical stress. A critical amplifying mechanism involves SGLT2-mediated glucose and sodium reabsorption in the proximal tubule, which reduces sodium chloride delivery to the macula densa and thereby attenuates tubuloglomerular feedback-mediated afferent vasoconstriction, perpetuating the hyperfiltration state. SGLT2 inhibitors exert their renoprotective effects in large part by restoring tubuloglomerular feedback signaling, promoting afferent vasoconstriction and reducing intraglomerular pressure.

### Metabolic Factors

Chronic hyperglycemia drives the accumulation of advanced glycation end-products in glomerular structures, which activate the receptor for AGEs (RAGE) and trigger downstream signaling through NF-kappaB, TGF-beta, and VEGF pathways. Non-enzymatic glycosylation of GBM and mesangial matrix proteins further contributes to structural damage. Additional metabolic pathways activated by hyperglycemia include the polyol pathway leading to sorbitol accumulation, protein kinase C activation, and the hexosamine pathway. Oxidative stress, primarily through mitochondrial superoxide generation, is the unifying mechanism driving all major diabetic pathways and represents a central therapeutic target.

### Inflammatory and Fibrotic Pathways

NF-kappaB activation promotes the expression of MCP-1 and ICAM-1, resulting in macrophage infiltration and interstitial inflammation. TGF-beta is the master fibrogenic cytokine in DKD, driving both mesangial matrix expansion and tubulointerstitial fibrosis. Endothelin-1 contributes to vasoconstriction, inflammation, and fibrosis, and is the target of emerging therapies such as sparsentan and atrasentan. Mineralocorticoid receptor overactivation drives inflammation and fibrosis through mechanisms independent of aldosterone levels, providing the rationale for finerenone as a therapeutic agent.

### Podocyte Injury

Podocyte injury in DKD manifests as hypertrophy, detachment, and progressive loss, termed podocytopenia. The resulting reduction in podocyte density leaves areas of bare GBM that inevitably progress to glomerulosclerosis. Key mediators of podocyte injury include VEGF dysregulation, mechanical stress from intraglomerular hypertension, and oxidative injury.

<image>Comprehensive pathophysiology diagram of diabetic kidney disease showing the interconnected hemodynamic and metabolic pathways. Center the diagram on the glomerulus. Left side (hemodynamic): show afferent arteriolar vasodilation (nitric oxide, prostaglandins) and efferent vasoconstriction (angiotensin II) causing glomerular hypertension. Include SGLT2-mediated reduced NaCl delivery to macula densa perpetuating TGF-mediated afferent dilation. Show SGLT2 inhibitor mechanism restoring TGF. Right side (metabolic): show hyperglycemia activating four pathways (AGE/RAGE, polyol, PKC, hexosamine) converging on oxidative stress and NF-kappaB activation. Bottom: show downstream injury pathways including TGF-beta-driven mesangial expansion and fibrosis, endothelin-1-mediated inflammation, podocyte injury and loss, and MR overactivation. Include drug targets: SGLT2i, RAAS blockade, finerenone (MR), endothelin antagonists, and GLP-1 RA.</image>

## Natural History and Staging

### Classic Progression (Mogensen Classification for T1DM)

The Mogensen classification describes five stages of DKD progression in type 1 diabetes. Stage 1 is characterized by glomerular hyperfiltration with a GFR exceeding 150 mL/min and renal hypertrophy, without albuminuria. Stage 2 is the silent phase, in which GBM thickening and mesangial expansion are detectable on biopsy but albuminuria remains normal. Stage 3 represents incipient nephropathy with microalbuminuria, defined as 30 to 300 mg per day or a UACR of 30 to 300 mg/g. Stage 4 is overt nephropathy with macroalbuminuria exceeding 300 mg per day, accompanied by declining GFR and hypertension. Stage 5 represents end-stage renal disease with a GFR below 15 mL/min.

### Non-Albuminuric DKD

Non-albuminuric DKD is increasingly recognized as a distinct phenotype, affecting 30 to 40 percent of type 2 diabetes patients with an eGFR below 60 who maintain normal albuminuria. This pattern may represent predominant vascular and ischemic pathology rather than the classic glomerular disease of traditional DKD. Despite the absence of albuminuria, these patients remain at high cardiovascular and renal progression risk. Importantly, SGLT2 inhibitors and finerenone provide benefit regardless of albuminuria status, ensuring that this population is not overlooked in treatment considerations.

## Renal Pathology

### Light Microscopy

The earliest histologic change on light microscopy is diffuse mesangial expansion, characterized by diffuse PAS-positive matrix accumulation. Nodular glomerulosclerosis, known as Kimmelstiel-Wilson nodules, is pathognomonic for DKD but is present in only 15 to 30 percent of cases. A distinctive feature of diabetic nephropathy is arteriolar hyalinosis affecting both the afferent and efferent arterioles, which distinguishes it from other forms of hypertensive nephrosclerosis that typically affect only the afferent arteriole. Uniform thickening of the glomerular basement membrane is another characteristic finding. Tubular atrophy and interstitial fibrosis correlate most closely with the degree of GFR decline.

### Tervaert Classification (2010)

The Tervaert classification provides a standardized grading system for diabetic glomerulosclerosis. Class I is defined by GBM thickening alone, requiring electron microscopy for diagnosis. Class IIa demonstrates mild mesangial expansion, while class IIb shows severe mesangial expansion. Class III is characterized by nodular sclerosis corresponding to Kimmelstiel-Wilson nodules. Class IV represents advanced diabetic glomerulosclerosis with more than 50 percent global sclerosis.

### When to Biopsy

Most cases of DKD are diagnosed clinically without the need for renal biopsy. However, biopsy is indicated when atypical features are present, including abrupt onset of proteinuria, active urine sediment with red blood cell casts, rapid GFR decline disproportionate to the degree of diabetes, absence of diabetic retinopathy in type 1 diabetes, or a short diabetes duration of less than 5 years. Non-diabetic kidney disease is found on biopsy in 30 to 40 percent of type 2 diabetes patients who present with atypical features, underscoring the importance of maintaining a broad differential diagnosis.

## Management

### Glycemic Control

The DCCT/EDIC trial in type 1 diabetes demonstrated that intensive glycemic control targeting a hemoglobin A1c of approximately 7 percent reduced the development of microalbuminuria by 39 percent and macroalbuminuria by 54 percent. The UKPDS trial showed that intensive glycemic control reduced microvascular complications in type 2 diabetes. The ADVANCE trial demonstrated that targeting an A1c below 6.5 percent reduced nephropathy with a hazard ratio of 0.79. However, the ACCORD trial established that overly aggressive glycemic targets below 6.0 percent increased mortality, establishing a lower limit of benefit. Current KDIGO 2024 guidelines recommend an individualized A1c target of 6.5 to 7.5 percent for most patients, with higher targets of 7.5 to 8.0 percent appropriate for those with advanced CKD, high hypoglycemia risk, or limited life expectancy. Continuous glucose monitoring is preferred over A1c in advanced CKD, as A1c becomes unreliable due to altered red blood cell lifespan, erythropoietin therapy, and iron deficiency.

### RAAS Blockade

ACE inhibitors or angiotensin receptor blockers represent the first-line therapy for DKD with albuminuria, defined as a UACR above 30 mg/g. This recommendation is supported by landmark trials including RENAAL for losartan, IDNT for irbesartan in overt nephropathy, and IRMA-2 for irbesartan in the prevention of progression from microalbuminuria to macroalbuminuria. These agents should be titrated to the maximum tolerated dose, and clinicians should accept up to a 30 percent rise in serum creatinine as a hemodynamic effect reflecting reduced intraglomerular pressure. Dual RAAS blockade combining ACE inhibitors with ARBs has been shown to be harmful in the ONTARGET and VA NEPHRON-D trials, which demonstrated increased hyperkalemia and acute kidney injury without benefit. Similarly, direct renin inhibitors should not be combined with ACE inhibitors or ARBs, as the ALTITUDE trial showed increased adverse events with this combination.

### SGLT2 Inhibitors (Foundational Therapy)

SGLT2 inhibitors have emerged as foundational therapy for DKD based on a series of landmark trials. The CREDENCE trial demonstrated a 30 percent reduction in the primary renal composite endpoint with canagliflozin in type 2 diabetes patients with DKD and an eGFR of 30 to 90 with a UACR of 300 to 5000. The DAPA-CKD trial showed a 39 percent reduction in the renal composite with dapagliflozin, with benefit observed in both diabetic and non-diabetic CKD, in patients with an eGFR of 25 to 75. The EMPA-KIDNEY trial demonstrated a 28 percent reduction with empagliflozin, extending the evidence to patients with an eGFR of 20 to 45 regardless of albuminuria status. The mechanism of renoprotection extends beyond hemodynamic effects of tubuloglomerular feedback restoration and reduced intraglomerular pressure to include anti-inflammatory and anti-fibrotic properties and reduced tubular workload. SGLT2 inhibitors can be initiated at an eGFR of 20 mL/min or above and continued until dialysis or transplant. The initial eGFR dip of 2 to 5 mL/min observed after initiation is a hemodynamic effect that is protective and should not prompt discontinuation. Clinicians should monitor for the risk of euglycemic diabetic ketoacidosis and hold these agents perioperatively and during acute illness.

### Finerenone (Non-Steroidal MRA)

Finerenone is a non-steroidal mineralocorticoid receptor antagonist that provides selective MR antagonism without the anti-androgenic side effects associated with spironolactone, and carries a lower risk of hyperkalemia. The FIDELIO-DKD trial demonstrated an 18 percent reduction in the primary renal composite endpoint, including sustained eGFR decline, kidney failure, and renal death, in type 2 diabetes patients with DKD already on maximized RAAS blockade. The FIGARO-DKD trial showed a 13 percent reduction in the cardiovascular composite. The pooled FIDELITY analysis confirmed consistent renal and cardiovascular benefits across both trials. Finerenone is indicated for type 2 diabetes with DKD in patients with a UACR of 30 mg/g or above and an eGFR of 25 or above who are already on maximized ACE inhibitor or ARB therapy. Potassium monitoring is essential, with the drug held if potassium exceeds 5.5 mEq/L and not initiated if potassium is above 5.0.

### GLP-1 Receptor Agonists

The FLOW trial, studying semaglutide and published in 2024, demonstrated a 24 percent reduction in the primary renal composite in type 2 diabetes patients with DKD, establishing semaglutide as the first GLP-1 receptor agonist with proven kidney outcomes benefit in a trial specifically powered for renal endpoints. The mechanisms of renal benefit include glycemic control, weight loss, anti-inflammatory effects, and direct tubular effects. GLP-1 receptor agonists should be considered in type 2 diabetes patients with DKD, particularly those with concomitant obesity and cardiovascular risk. Semaglutide can be used at an eGFR of 15 mL/min or above without dose adjustment.

### Endothelin Receptor Antagonists

Atrasentan, a selective endothelin A receptor antagonist, was evaluated in the SONAR trial, which demonstrated a 35 percent reduction in the renal composite in type 2 diabetes patients with DKD. However, the trial required exclusion of patients with significant fluid retention risk, highlighting the major limitation of endothelin receptor antagonists. Sparsentan, a dual endothelin A and angiotensin II type 1 receptor antagonist, was evaluated in the DUPLEX trial for FSGS and is under investigation for DKD. The risk of fluid retention continues to limit the broader adoption of this drug class, necessitating careful patient selection.

<image>Comprehensive treatment pyramid for diabetic kidney disease showing the evidence-based stepwise approach. Base layer: lifestyle modifications (sodium restriction <2g/day, moderate protein intake 0.8 g/kg/day, exercise, smoking cessation, weight management). Second layer: RAAS blockade (ACEi or ARB, titrate to max dose, landmark trials RENAAL/IDNT/IRMA-2). Third layer: SGLT2 inhibitor (dapagliflozin, empagliflozin, or canagliflozin; landmark trials CREDENCE/DAPA-CKD/EMPA-KIDNEY). Fourth layer: finerenone (non-steroidal MRA; FIDELIO/FIGARO trials; add if UACR ≥30 on RAAS blockade). Fifth layer: GLP-1 receptor agonist (semaglutide; FLOW trial). Top layer: additional considerations (BP target <130/80, glycemic target HbA1c 6.5-7.5%, statin, antiplatelet if CV risk). Show eGFR thresholds for each therapy initiation on the side.</image>

| Therapy | Landmark Trial(s) | Risk Reduction | eGFR Threshold for Initiation | Key Mechanism |
|---------|-------------------|----------------|------------------------------|---------------|
| ACEi/ARB | RENAAL, IDNT, IRMA-2 | 16–33% renal composite | Any eGFR (with UACR ≥30 mg/g) | ↓ Intraglomerular pressure via efferent vasodilation |
| SGLT2 inhibitor | CREDENCE, DAPA-CKD, EMPA-KIDNEY | 28–39% renal composite | ≥20 mL/min | Restore TGF; ↓ intraglomerular pressure; anti-inflammatory |
| Finerenone (NS-MRA) | FIDELIO-DKD, FIGARO-DKD | 18% renal, 13% CV composite | ≥25 mL/min (UACR ≥30 on max RAAS) | MR antagonism → ↓ inflammation/fibrosis |
| GLP-1 RA (semaglutide) | FLOW (2024) | 24% renal composite | ≥15 mL/min | Glycemic control, weight loss, anti-inflammatory, direct tubular |
| Endothelin RA (atrasentan) | SONAR | 35% renal composite | Investigational | ↓ Endothelin-mediated vasoconstriction/fibrosis; fluid retention risk |

### Blood Pressure and Other Targets

Blood pressure should be controlled to a target below 130/80 mmHg as recommended by KDIGO 2021. For diabetic CKD, a target below 120 systolic per SPRINT considerations is not directly applicable, as diabetes was excluded from the SPRINT trial. Statin therapy is recommended for all DKD patients with an eGFR below 60 or albuminuria, supported by the SHARP and CARDS trials. Smoking cessation is critical, as smoking accelerates DKD progression. Moderate protein restriction to 0.8 g/kg/day is recommended, though very low protein diets should be avoided. Sodium restriction to less than 2 grams per day enhances the efficacy of both RAAS blockade and SGLT2 inhibitors.

## Key Clinical Pearls

- The four pillars of DKD management are now: (1) RAAS blockade, (2) SGLT2 inhibitor, (3) finerenone, and (4) GLP-1 RA; all should be considered in eligible patients with additive benefit
- SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback; the initial eGFR dip is hemodynamic and protective — do not discontinue
- Finerenone provides additional renal and cardiovascular benefit on top of maximized RAAS blockade + SGLT2i; it targets inflammation and fibrosis via MR antagonism
- The FLOW trial established semaglutide as the first GLP-1 RA with proven kidney outcomes benefit; GLP-1 RAs are now a key component of DKD therapy
- Non-diabetic kidney disease coexists in 30-40% of T2DM patients with renal disease; biopsy when atypical features are present (active sediment, rapid decline, no retinopathy)

## References
1. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). *N Engl J Med*. 2019;380(24):2295-2306.
2. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). *N Engl J Med*. 2020;383(15):1436-1446.
3. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). *N Engl J Med*. 2020;383(23):2219-2229.
4. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). *N Engl J Med*. 2024;391(2):109-121.
5. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY). *N Engl J Med*. 2023;388(2):117-127.